- The disease
- Severe-to-profound sensorineural hearing loss (SNHL) is a condition in which the sensory hair cells of the inner ear are damaged or absent, preventing sound signals from reaching the auditory nerve. It can affect one or both ears and may be congenital or acquired. When bilateral, it significantly impairs speech understanding and communication. Conventional hearing aids amplify sound but provide limited benefit when hearing loss reaches the severe-to-profound range.
- What the asset is trying to do
- A cochlear implant is a surgically implanted electronic device that bypasses damaged hair cells in the inner ear and directly stimulates the auditory nerve with electrical signals. An external sound processor captures audio, converts it into a coded signal, and transmits it to an internal receiver-stimulator, which then delivers electrical pulses via an electrode array placed in the cochlea. This approach differs from hearing aids, which amplify acoustic sound, because it replaces the function of the missing or non-functional hair cells entirely. The CI600 series refers to Cochlear Limited's current generation of implantable receivers and electrode arrays.
- What the trial is measuring, and why it matters
- The active post-market study (per ClinicalTrials.gov NCT06867380) is evaluating sound coding enhancements in adult cochlear implant recipients by comparing an investigational sound coding strategy against Cochlear's default strategy. A separate not-yet-recruiting study (NCT07338864) is designed to evaluate clinical benefit, performance, and safety of the Nucleus Nexa cochlear implant series (CI1032, CI1022, CI1012) in adults. Endpoints across these studies relate to hearing performance and device safety outcomes, which are standard measures used to support post-market surveillance and iterative product development.
- Efficacy benchmarks in this setting
- For adults with severe-to-profound bilateral SNHL, cochlear implantation is an established standard of care supported by decades of clinical evidence. Published studies have reported improvements in open-set sentence recognition scores following cochlear implantation; for example, Gifford et al. have documented mean post-implant sentence recognition scores in quiet exceeding 60% in appropriately selected adult candidates, though outcomes vary widely by patient factors (per Gifford et al., Ear and Hearing, various years). Regulatory bodies including the US FDA have cleared cochlear implants for bilateral severe-to-profound SNHL in adults and children meeting audiological criteria (per FDA device approval records). The active Cochlear trials listed here are post-market investigations evaluating enhancements to existing approved devices; their early data, if any, are not statistically comparable to the established performance benchmarks of the approved product line.